Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.48 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140923 | 0.86 | MALT1 (0.50) | MALT1TRPV1KMT2A | |
| SCHEMBL20133581 | 0.85 | MTOR (0.62) | MALT1MTORRPTORMLST8TRPV1 | |
| SCHEMBL20141580 | 0.84 | MTOR (0.49) | MTORRPTORMLST8KMT2A | |
| SCHEMBL20149906 | 0.83 | MTOR (0.54) | MALT1MTORRPTORMLST8TRPV1 | |
| SCHEMBL20133783 | 0.83 | MTOR (0.60) | MALT1MTORRPTORMLST8TRPV1 | |
| SCHEMBL20149904 | 0.83 | MTOR (0.52) | MALT1MTORRPTORMLST8 | |
| SCHEMBL21360417 | 0.82 | MTOR (0.50) | MTORRPTORMLST8 | |
| SCHEMBL20133849 | 0.82 | MTOR (0.57) | MALT1MTORRPTORMLST8KMT2A | |
| SCHEMBL20133576 | 0.81 | MTOR (0.75) | MALT1MTORRPTORMLST8TRPV1 | |
| SCHEMBL22693247 | 0.81 | MTOR (0.59) | MALT1MTORRPTORMLST8GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MALT1 1966/4885MTOR 1/4885RPTOR 3/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MALT1 1966/4885MTOR 1/4885RPTOR 3/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MALT1 1966/4885MTOR 1/4885RPTOR 3/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MALT1 1966/4885MTOR 1/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.